Broadly Neutralizing Influenza Hemagglutinin Stem-Specific Antibody CR8020 Targets Residues that Are Prone to Escape due to Host Selection Pressure
Broadly neutralizing antibodies (bNAb) that target a conserved region of a viral antigen hold significant therapeutic promise. CR8020 is a bNAb that targets the stem region of influenza A virus (IAV) hemagglutinin (HA). CR8020 is currently being evaluated for prophylactic use against group 2 IAVs in...
Gespeichert in:
Veröffentlicht in: | Cell host & microbe 2014-05, Vol.15 (5), p.644-651 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Broadly neutralizing antibodies (bNAb) that target a conserved region of a viral antigen hold significant therapeutic promise. CR8020 is a bNAb that targets the stem region of influenza A virus (IAV) hemagglutinin (HA). CR8020 is currently being evaluated for prophylactic use against group 2 IAVs in phase II studies. Structural and computational analyses reported here indicate that CR8020 targets HA residues that are prone to antigenic drift and host selection pressure. Critically, CR8020 escape mutation is seen in certain H7N9 viruses from recent outbreaks. Furthermore, the ability of the bNAb Fc region to effectively engage activating Fcγ receptors (FCγR) is essential for antibody efficacy. In this regard, our data indicate that the membrane could sterically hinder the formation of HA-CR8020-FcγRIIa/HA-IgG-FcγRIIIa ternary complexes. Altogether, our analyses suggest that epitope mutability and accessibility to immune complex assembly are important attributes to consider when evaluating bNAb candidates for clinical development.
[Display omitted]
•HA residues targeted by the CR8020 antibody are susceptible to host selection pressure•Influenza HA mutations have the potential to negatively impact CR8020 activity•Known CR8020 escape mutation is found in an H7N9 outbreak virus•Membrane may sterically hinder FcγR binding to Fc within the HA-CR8020 immune complex
The influenza virus hemagglutinin-stem-specific antibody CR8020 is currently in clinical trials. Modeling studies of Tharakaraman et al. indicate that the CR8020 epitope is susceptible to antigenic drift and under host selection pressure. Furthermore, CR8020 shows poor affinity toward current H7N9 hemagglutinin, and the targeted epitope impacts CR8020 binding to FcγRs. |
---|---|
ISSN: | 1931-3128 1934-6069 1934-6069 |
DOI: | 10.1016/j.chom.2014.04.009 |